Get the Stockscreener App
8.59
1.72%
-0.15
Pre-market:
8.56
-0.03
-0.35%
CorMedix Inc stock is traded at $8.59, with a volume of 1.41M.
It is down -1.72% in the last 24 hours and up +13.77% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$8.74
Open:
$8.912
24h Volume:
1.41M
Relative Volume:
1.14
Market Cap:
$673.90M
Revenue:
$400.05M
Net Income/Loss:
$181.01M
P/E Ratio:
4.0918
EPS:
2.0993
Net Cash Flow:
$194.71M
1W Performance:
+0.59%
1M Performance:
+13.77%
6M Performance:
-24.18%
1Y Performance:
-41.00%
1-Day Range:
$8.49
$8.912
1-Week Range:
$8.46
$9.0851
52-Week Range:
$6.125
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
8.59 | 673.90M | 400.05M | 181.01M | 194.71M | 2.0993 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath MomentumLearn Why - Yahoo Finance
CorMedix Inc. (CRMD) Reports Q1 2026 Results - Insider Monkey
CorMedix (CRMD) holder reports 4.62M shares, 5.89% stake - Stock Titan
CorMedix (CRMD): Investor reports 4.62M shares, 5.89% stake - Stock Titan
5 Most Profitable Small Cap Stocks to Buy - Insider Monkey
Why Did CRMD Stock Tumble Over 11% Today? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
CRMD Q1 2026 Earnings: EPS Beat of 31.72% Drives Stock HigherProfit Recovery Report - newsline.com
Federal appeals court upholds CorMedix patent win over Nexus - Investing.com UK
Federal Circuit Affirms CorMedix Patent Victory, Blocking Nexus Generic MINOCIN® Launch Until Patent Expiration 1 - minichart.com.sg
Federal appeals court upholds CorMedix patent win over Nexus By Investing.com - Investing.com South Africa
Appeals court upholds CorMedix (NASDAQ: CRMD) MINOCIN® patents and injunction - Stock Titan
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation - Yahoo Finance
Can CorMedix Turn Launch Execution Into Momentum? - Kalkine Media
CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market - Stocktwits
CRMD Q1 2026 Earnings: Strong EPS Beat Drives Stock HigherPost-Earnings Drift - newsline.com
CorMedix eyes REZZAYO expansion as DefenCath reimbursement shift looms - MSN
CRMD Technical Analysis | Trend, Signals & Chart Patterns | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CRMD Q1 2026 Earnings: Strong EPS Beat as Company Advances Commercial EffortsNet Profit Margin - newsline.com
Avoiding Lag: Real-Time Signals in (CRMD) Movement - Stock Traders Daily
CRMD Q1 2026 Earnings: Positive EPS Surprise Despite Absence of RevenueGross Profit Margin - The Legal Advocate
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run - Seeking Alpha
Cormedix outlines $325M-$345M 2026 net revenue outlook amid TDAPA transition - MSN
CorMedix Q1 earnings call highlights - MSN
CorMedix (CRMD) Tests Support Zone After Modest DeclineFade Trade - newsline.com
CRMD: Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets - TradingView
CRMD Q1 earnings beat on DefenCath momentum, guidance raised - MSN
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms - MarketBeat
CorMedix stock jumps as DefenCath fuels Q1 beat, 2026 outlook raised - MSN
Cormedix Earnings Call Highlights Surging Growth, New Risks - TipRanks
CorMedix banks on DefenCath sales in Q4 as Melinta adds upside - MSN
UBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMD - MarketBeat
Needham Maintains CorMedix (CRMD) Buy Recommendation - MSN
Discipline and Rules-Based Execution in CRMD Response - Stock Traders Daily
CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat (NASDAQ:CRMD) - Seeking Alpha
HC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD) - MarketBeat
Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)? - Yahoo Finance
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results - simplywall.st
A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year Guidance - Yahoo Finance
CorMedix Inc $CRMD Shares Bought by Vanguard Group Inc. - MarketBeat
RBC Capital Keeps Their Buy Rating on Cormedix (CRMD) - The Globe and Mail
CorMedix (CRMD) Q1 earnings and revenues beat estimates - MSN
CorMedix Inc.Common Stock (NQ: CRMD - The Chronicle-Journal
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised - The Globe and Mail
A Quick Look at Today's Ratings for CorMedix(CRMD.US), With a Forecast Between $13 to $15 - Moomoo
Deep Track (CRMD) files Schedule 13G/A reporting 7.94% ownership - Stock Titan
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences - marketscreener.com
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):